Drug-induced bullous pemphigoid (DBP), a rare phenomenon, has been observed with certain biologics, particularly anti-TNF-α agents and anti-IL-12/IL-23 drugs such as ustekinumab—with only limited case reports associated with guselkumab (anti-IL-23) (3). Here, IL23A is linked to bullous pemphigoid.